Natural Products and Synthetic Biology: Where We Are and Where We Need To Go
ABSTRACT The biosynthetic talent of microorganisms has been harnessed for drug discovery for almost a century. Microbial metabolites not only account for the majority of antibiotics available today, but have also led to anticancer, immunosuppressant, and cholesterol-lowering drugs. Yet, inherent cha...
Guardado en:
Autores principales: | Sylvia Kunakom, Alessandra S. Eustáquio |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7e0f0800bc6447f2aeacddf326f43dc4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Tripod for Bacterial Natural Product Discovery: Genome Mining, Silent Pathway Induction, and Mass Spectrometry-Based Molecular Networking
por: Daniela B. B. Trivella, et al.
Publicado: (2018) -
Drug Design: Where We Are and Future Prospects
por: Giuseppe Zagotto, et al.
Publicado: (2021) -
Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
por: Harun Norshidah, et al.
Publicado: (2021) -
Dermatology education in skin of colour: where we are and where do we go?
por: Joshua Onasanya, et al.
Publicado: (2021) -
Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
por: Huihua Zeng, et al.
Publicado: (2021)